Charles Schwab Investment Management Inc. Grows Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Charles Schwab Investment Management Inc. grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 476,799 shares of the company’s stock after acquiring an additional 14,264 shares during the period. Charles Schwab Investment Management Inc.’s holdings in IDEXX Laboratories were worth $264,647,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Valley National Advisers Inc. boosted its stake in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares during the last quarter. OFI Invest Asset Management bought a new position in IDEXX Laboratories during the third quarter worth $25,000. Venturi Wealth Management LLC lifted its stake in IDEXX Laboratories by 226.3% during the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after purchasing an additional 43 shares during the last quarter. Geo Capital Gestora de Recursos Ltd bought a new position in IDEXX Laboratories during the third quarter worth $28,000. Finally, Covestor Ltd lifted its stake in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after purchasing an additional 28 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IDXX. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group raised their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $580.88.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $487.07 on Thursday. The firm has a market capitalization of $40.23 billion, a price-to-earnings ratio of 47.15, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock’s fifty day moving average is $519.60 and its 200-day moving average is $514.34.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $2.05 earnings per share. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.05 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.